A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510017-26-00

Acronym

CT-P51 1.1

Enrollment

Registered

2024-08-23

Start date

2024-10-02

Completion date

Unknown

Last updated

2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and III Melanoma, Completely Resected Stage IIB, IIC

None listed

Sex/Gender

All

Age

18 Years to No maximum

Croatia, Italy, Poland, Romania, Slovenia, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026